Document Detail

Drug design for ever, from hype to hope.
Jump to Full Text
MedLine Citation:
PMID:  22252446     Owner:  NLM     Status:  MEDLINE    
In its first 25 years JCAMD has been disseminating a large number of techniques aimed at finding better medicines faster. These include genetic algorithms, COMFA, QSAR, structure based techniques, homology modelling, high throughput screening, combichem, and dozens more that were a hype in their time and that now are just a useful addition to the drug-designers toolbox. Despite massive efforts throughout academic and industrial drug design research departments, the number of FDA-approved new molecular entities per year stagnates, and the pharmaceutical industry is reorganising accordingly. The recent spate of industrial consolidations and the concomitant move towards outsourcing of research activities requires better integration of all activities along the chain from bench to bedside. The next 25 years will undoubtedly show a series of translational science activities that are aimed at a better communication between all parties involved, from quantum chemistry to bedside and from academia to industry. This will above all include understanding the underlying biological problem and optimal use of all available data.
G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Related Documents :
20357466 - A thermoregulatory behavior.
24708146 - A qualitative review of psychosocial risk factors associated with caffeinated alcohol use.
19785486 - Prorelationship maintenance behaviors: the joint roles of attachment and commitment.
15641886 - Rewarding leadership and fair procedures as determinants of self-esteem.
17806956 - Correction.
22221936 - Global haemostasis assays, from bench to bedside.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-01-18
Journal Detail:
Title:  Journal of computer-aided molecular design     Volume:  26     ISSN:  1573-4951     ISO Abbreviation:  J. Comput. Aided Mol. Des.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-02-14     Completed Date:  2012-07-23     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  8710425     Medline TA:  J Comput Aided Mol Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  137-50     Citation Subset:  IM    
Adelard Institute, Manchester, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Academies and Institutes / trends
Drug Design*
Drug Industry / trends
Translational Medical Research / trends*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Comput Aided Mol Des
ISSN: 0920-654X
ISSN: 1573-4951
Publisher: Springer Netherlands, Dordrecht
Article Information
Download PDF
© The Author(s) 2012
Received Day: 22 Month: 11 Year: 2011
Accepted Day: 5 Month: 12 Year: 2011
Electronic publication date: Day: 18 Month: 1 Year: 2012
pmc-release publication date: Day: 18 Month: 1 Year: 2012
Print publication date: Month: 1 Year: 2012
Volume: 26 Issue: 1
First Page: 137 Last Page: 150
ID: 3268973
PubMed Id: 22252446
Publisher Id: 9519
DOI: 10.1007/s10822-011-9519-9

Drug design for ever, from hype to hope
G. Seddon1
V. Lounnas2
R. McGuire3
T. van den Bergh4
R. P. Bywater5
L. Oliveira6
G. Vriend2 Address:
1Adelard Institute, Manchester, UK
2CMBI, Radboud University Nijmegen Medical Centre, Geert Grooteplein 26–28, 6525 GA Nijmegen, The Netherlands
3BioAxis Research, Bergse Heihoek 56, Berghem, 5351 SL The Netherlands
4Bio-Prodict, Dreijenplein 10, 6703 HB Wageningen, The Netherlands
5Magdalen College, Oxford, UK
6Sao Paulo Federal University (UNIFESP), Sao Paulo, Brazil


Life expectancy of man, and especially man in the western world, increased by more than 2 days per week for the whole previous century [1]. Much of this dramatic increase is to the credit of hygiene, but medicines, and especially antibiotics and vaccines, have contributed significantly too. In the first world war, for example, almost as many soldiers died of disease as of bullets [2]. During the second world war this unfortunate situation got ‘remedied’ by the introduction of sulphonamides and penicillin [3].

At this moment medical doctors around the world can write prescriptions for tens of thousands of medicines [4], and an even larger number is available of herbal medicines, homeopathic wonder-cures, and other preparations for which the medicinal value has not been proven [5]. Most medicines function by interacting with proteins in the body. Of the more than twenty thousand protein types in our body less than five hundred are targeted by all these medicines [6]. This, of course, gives hope for the future of drug design because most proteins are still available as a target for which a blockbuster drug can be designed.

Despite massive, world-wide efforts the number of new molecular entities (NMEs) that the FDA approves per year for use as medicines certainly isn’t growing [7], while the amount of money involved goes up much faster than inflation [7] even when we include Obama’s Troubled Asset Relief Program [8].

This journal (JCAMD) has published many, many articles on techniques that according to the authors of these articles were the holy grail for drug design, and that in today’s reality are just good tools used in this process. Following a path familiar in science, someone has a good idea, gives it a name and publishes it. Others follow suit and publish improvement after improvement, after which yet others start testing all similar methods. An example is the use of support vector machines for ligand selection. This was introduced in 2000 [10] and only 3 years of improvements were needed before the first comparison methods were published [11]. Figure 1 illustrates the desperation of pharmaceutical industries. The ever increasing costs mainly result from development and marketing [12] and, unfortunately for us, not from research. This might explain why each time a new drug design research tool gets published pharmaceutical industries immediately jump on it and give it a hype status.

A brief history of tools

The first hype in drug design was born out of the famous article by Hol [13] in which he coined the name ‘rational drug design’ for all protein-structure based techniques, thereby implicitly calling all methods that actually worked, such as screening or luck, irrational; see Fig. 2.

It is not by eye that we can determine either the fitness of a ligand for a pocket, or the safety or efficacy of a drug. It does not seem illogical to assume that the founders of JCAMD were at least subconsciously dealing with the oversimplification implied by Fig. 2 when they started this journal. And we believe that most articles published in JCAMD have dealt with aspects of drug design ‘left out’ of Fig. 2. The advent of faster computers like first the VAX/VMS, then supercomputers such as the CRAY, and finally the PC, have allowed scientist to numerically solve chemical problems of ever increasing size and complexity. Semi-empirical quantum calculation methods have been devised to calculate the chemically relevant aspects of the electronic wave-functions associated with small organic molecules and thus compute their 3D dimensional structures as well as the energy of their conformers [1519]. All the techniques derived in this domain are referred to as ligand-based drug design. In parallel, the development of molecular mechanics force fields combined with the fact that Newton’s equations of motion could be solved for entire proteins in their aqueous environments were true innovations in the investigation of the structure function relationships [2028]. Thus, not only the geometry and the potential energy surface of macromolecular assemblies could be calculated but also their dynamic and thermodynamic properties [29, 30]. For the early computational chemists this opened the perspective of testing at will the energy of interactions between protein targets and large collections of small molecule ligands [29, 31, 32]. The original thoughts that this would replace experimental validation processes, though, have long been shown to be a nice dream at best. The perception that the underlying mechanism of protein–ligand recognition would be unravelled and would thus allow what ever since has been called structure-based drug design has never looked so clear and promising as at that particular moment in 1986.

With the exception of a very small fraction of ligands that are purely rigid, most bioactive ligands have a number of rotatable bonds that make them flexible. The values of the torsion angles in ligands are determined by the valence electrons of the atoms. The development of empirical molecular mechanics force field in the late 1970s [33, 34] have allowed for the in silico determination of the geometries (low energy conformers) of ligands in vacuo. Application of these methods relies on two underlying assumptions: (1) that the conformation of the dissolved ligand corresponds closely to its gas-phase conformation [35]; and (2) that the biologically active conformation of the ligand is likely to be found among the set of low energy conformers of the isolated ligand [36, 37]. The combined knowledge of the ligand structure (determined by NMR or X-ray), the measured binding affinities, and the spatial overlay of the low energy conformations should then be sufficient to establish a structure activity relationship [38] and pinpoint the spatial organization of the recurrent chemical features correlated with activity (pharmacophore). This paved the way for a series of successes for ligand-based drug design [e.g. 39, 40, 16]. However, although it seems fairly reasonable at first sight, both assumptions in practice proved to be incomplete and/or insufficient [4150].

The computational process by which the complementary aspects between a ligand and a receptor binding site can be ascertained has been explored with the design of specifically dedicated docking programmes. Early docking methods were based uniquely on assessing the shape complementarity [51] between a pocket in the 3D structure of a protein and low energy conformers of a ligand. The approach was computationally cumbersome due to the need to systematically search all possible ligand orientations within the pocket and scoring each of these poses by its steric hindrance. Subsequent developments have taken place in several directions: improved scoring functions [5263] different ways to deal with ligand flexibility [60, 6472], and most recently also ways to deal with receptor flexibility [7378]. Fundamental research has been performed into directions such as desolvation energies [7983], or other aspects of the force fields used for scoring docking poses [66, 78, 8496].

The idea to calculate from first principles all atomic motions occurring in an active enzyme in its aqueous environment has attracted many scientists to computer aided molecular design. Starting with the atomic loci obtained from the X-ray structure of en enzyme it can be envisaged to integrate Newton’s equations [29, 31]. A series of snapshots describing the trajectory of the enzyme over time could thus be produced and ensemble average properties calculated based on Boltzmann’s ergodic hypothesis. The near infinite computer time needed for such experiments muted this field till concepts from alchemy could be embraced. In silico, one is not bound by the sequential order of events that govern paths between states, and hence so-called thermodynamic cycle methods could be developed that replaced chemical steps with alchemical steps that in principle should lead to the same outcome [29, 30, 97, 98].

Comparative Molecular Field Analysis (CoMFA) is based on the overlay of active ligands [99, 100102]. Initially, the technique was more a concept than an effective tool as computer power was very limited and molecular descriptors as well as dedicated algorithms needed to be developed [103]. The underlying idea that the 3D dimensional steric/non-bonded (Van der Waals) and electrostatic potential fields generated by the spatial organization of the chemical features around the scaffold of a ligand (Fig. 3) play a fundamental role in the biomolecular receptor recognition was so intuitively right and the technique made a break-through in 1988 [99]. Examples of the application of the method are plentiful [100]. About 15% of all articles in JCAMD refer to the use of this technique, refined and applied in all sorts of ways to produce the overly famous quantitative structure activity relationship (QSAR) equations. However, CoMFA suffers from three drawbacks: (1) the alignment of the ligands in the pocket must be either known or gambled correctly; (2) the method has been established for rigid or quasi-rigid classes of molecules (e.g. steroids); and (3) the detailed influence of the protein pocket is not known which means that any feature that is not implicitly present in the training set will be missed [104109]. These nearly fatal drawbacks prevented the generalization of the method as a standalone solution to rational drug design. Certainly, the best way to apply CoMFA is to combine it with a pharmacophore model and a carefully conducted conformational study of the ligands [110].

Many drug design projects include at some stage knowledge of the 3D structure of the target protein, and homology modelling is normally used when neither X-ray nor NMR derived coordinates are available [111118]. Many computer programs were written for this purpose [119123] and the CASP competition [124] illustrates every 2 years where the field stands. Presently, YASARA seems to be performing very well [122], but many labs are working hard so this situation might change again in the future. For example, methods are under development that use PLIM [125] to provide a first fix on the ligand docking site where-after steered Molecular Dynamics is used to continue the trajectory to convergence.

Similar to the CASP competitions, the GPCR-DOCK [126, 127] competitions have evaluated the quality of docking software, but with the additional complexity that the target structures needed to be modelled before docking could be attempted. In recent years a whole series of studies have been published in which homology modelling, combined with other tools, proved a viable replacement for the cumbersome experimental determination of target structures [111, 114, 128, 129]. The good performance of two Dutch teams [130] in the recent GPCR Dock competition [127] beautifully illustrates the often mentioned fact that even the best tools only perform well in the hands of good scientists [131]. In this latter article we find the interesting quote “Interestingly enough, it is the model built with most human intervention which proves to be the best”.

In the early 1990s the radical new idea emerged that instead of the virtual and/or real screening of large libraries of already existing molecules to identify new bioactive hits, one could rather attempt to construct entirely new synthesizable molecular entities solely based on the knowledge of the active site of the pharmaceutical target enzyme. [132134]. To do so, small organic fragments composed of few atoms only must be assembled in silico inside the binding sites of enzymes in such a way that optimal protein–ligand, steric, and electronic complementarity is achieved [84, 125, 135141]. The major problem of this approach arises from the complexity of the active site landscape and the combinatorial vastness of all possible arrangements of fragments in the volume delineated by an enzyme active site [66, 142144]. How to choose the first fragment and where should it be positioned and oriented with respect to the inner surface of the binding pocket or cleft [143, 145, 146]? Which next fragment should be attached to it? [147]? The genetic algorithms [66, 142, 148150] have been invented which allow this concept to be realized within a tractable amount of computer time by performing random transformations on a ligand collection. These transformations are selection, mutation, and crossover, and are reminiscent of the corresponding evolutionary processes in biology underlying the optimisation of genes, hence their name ‘genetic algorithms’. Experience shows that these algorithms provide solutions that nicely fit the objective function, although it often is difficult to understand exactly why [66].

Randomly screening very large libraries containing up to 105 or even 106 chemical entities in in vitro enzymatic assays to produce leads has been the central paradigm of the pharmaceutical industry across the 1990s. However, after years of operating very expensive screening facilities, it has been realized that the hits produced were not of the expected quality. For example, often a bias is observed toward too lipophilic compounds that are impossible to optimize. Compared to the actual number of chemically entities (~infinite) the any amount of compounds that can be screened via this process is essentially zero [151, 152]. In parallel, computational chemists had inferred that screening could be successfully operated virtually throughout computers at all stages in the drug design process from hit identification via hit optimization to lead optimization [153162]. In each of these three stages virtual libraries can be created and filtered either using chemometrics to exclude molecules that obviously aren’t drug-like because of their predicted solubility or ADME/Tox properties, or using 3D chemical molecular descriptors (pharmacophores), or using docking results. Thus, libraries of compound that do not actually exist can be screened and a much smaller, manageable number of compounds selected. This is of particular advantage at the stage of lead optimization, when only few compounds are left. Scaffolds of lead compounds usually carry a number of branching points were chemical variation is allowed. The in silico creation of combinatorial libraries of all the variant compounds is a dramatically faster process than its in vitro counterpart [163165].

One of the main difficulties in establishing reliable and/or transferrable QSAR equations is that, even within a class of chemical analogues, ligand affinities may not respond linearly to the variation of one or several of the molecular descriptors that have been identified as related to activity. For instance, across a series of chemical substituents sorted by increasing polarity the measured affinity may respond linearly only for a restricted number of them because steric hindrance or global effect such as desolvation may penalize the binding of slightly larger groups. The modification of a branched group at another point around the scaffold may however allow some of the previously excluded ligands to become highly active. Indeed the mere addition of one methyl group may result in a sudden tenfold leap in potency, dramatically increasing ligand efficiency [166, 167]. It was demonstrated that these problems could be circumvented using artificial intelligence methods (neural network, support vector machine, etc.) that are insensitive to the spatial alignment of the ligand scaffolds and that are able to recognize particular combinations of properties distributed around the scaffold of a set of active ligands [168170]. Artificial intelligence can be ubiquitously implemented at various stages in the rational drug design process to improve results that can be otherwise be more uncertainly obtained with classical methods, especially when assessing general properties that are the result of the subtle combination of many different factors in relation to others such as drug-likeness [171]. Various examples of artificial intelligence applications and their limitations have been published in JCAMD [172175]. Notwithstanding the utility of artificial intelligence, normal intelligence remains useful in avoiding some of the all too common pitfalls in the derivation and application of QSAR models [176].

We apologise to the many authors of methods that didn’t make it into the above list (see ESM Table 1). Much good work has been done that the editors certainly wouldn’t allow us to include because citing all 1,200 articles published in JCAMD in the first 25 years would perhaps be a bit excessive. We could have mentioned the work by Che on privilege structures [177], or by Lotta et al. [178] on multivariate PLS modelling of data sets. The recent work by Zhou et al. [179] on the use of DFT calculation to accurately assess the existence of intermolecular H-bonds in docking instances. Sarmah et als [180] work on solvent effects also added significantly to the drug-designers toolbox, but the methods described in these articles didn’t achieve hype status.

Where do we stand today?

The rapid increase in costs of developing and marketing new medicines is not leaving the pharmaceutical industry untouched. Recent years have seen a strong concentration of activities in terms of mergers, buy-outs, and closures [7]. It may simply be, that a research-intensive industry like the pharmaceutical industry does not lend itself to the type of management that is common in consumer goods, fashion and footwear. It seems a paradox, though, that the high costs associated with drug design are caused by development, marketing, and legal fees, but when it comes to cost-reduction research departments are, euphemistically called, consolidated. The past years have also seen a consolidation of methods. JCAMD has published a large series of articles in which multiple methods have been combined. [22, 128, 129, 181185]. All these pipelines and otherwise combined methods speed up the use of the existing tools, and allow them to be applied to ever larger numbers of small molecules in ever shorter times.

Actually, there is a new hype raging at the moment, and it is called ‘translational science’. In the Wikipedia we find under translational research: “In the field of medicine, for example, it is used to translate the findings in basic research more quickly and efficiently into medical practice and, thus, meaningful health outcomes, whether those are physical, mental, or social outcomes”. In a sense, the recent spate of articles on combining existing techniques into more easily applicable super-tools fit nicely to this translational paradigm. It must be stated, though, that the translation science hype is feeling stiff competition from systems biology [186] and modelling pharmacokinetics and pharmacodynamics [187]. Between the lines we read in translational science that the pharmaceutical industry has finally realized that our deep lack of understanding of all aspects of the interaction of a medicine with a human being is the main cause for luck still being the most determining factor in the drug design process. Consequently, we see the out-sourcing budgets of the large pharmaceutical industries go up [188], and more and more fundamental research performed in academia is finding its way to small and medium size enterprises (SMEs) where it can be incorporated in their lean and mean research machines [9]. Big pharma will at some time buy either their products or the whole SMEs and convert validated targets and leads or even Phase I products into new medicines.

This new paradigm will probably also be proven a hype soon; only time can tell if translational research will rescue the pharmaceutical industry, or that it will only better illustrate what it all is that we don’t know yet. It remains a fact that better understanding the underlying biology, better treatment of all available data, and more intelligent combinations of data, information, and knowledge must be beneficial for the drug design process and thus, on the long run, for all of us.

If the pharmaceutical industry wants academia more involved in the drug design process they could themselves make a giant first step by making available all (or at least very many) X-ray structures of protein–ligand complexes. We estimate that the number of PDB [189, 190] files collecting computer dust in the pharmaceutical industry is considerably bigger than the 75,000 structures now in the PDB. We have discussed this possibility with industrial crystallographers who realized that they were sometimes sitting on thousands of structure files for which secrecy was no longer an issue. They remained nevertheless hesitant to even consider discussing with their management the release of these data in fear of paranoia based rejection. Another often heard rejection criterion is that they are a bit ashamed for these data because often these files have not been refined any further than was needed to answer the biological or pharmaceutical question at hand. We offer to set up a database for these files, and we offer to re-refine all industrial structures of protein–ligand complexes. We will then only release those coordinates to the wider public that pass certain minimal validation criteria [191]. Obviously, the files in this system will remain the property of the depositors. If one day deposition of coordinate files into the PDB becomes significantly easier, we can consider depositing all files in the PDB on behalf of the original depositors. It might seem a bold promise to re-refine perhaps even 100,000 structures, but the PDB_REDO experiment [192196] shows that today this can be done. In PDB_REDO we significantly improved 85% of all presently available PDB files that were solved by X-ray. It seems likely that structures that often have been minimally refined can be improved even easier. One can even envisage that industries would like to look back at their own coordinates after we went through the elaborate and time consuming refinement process for them; in management speak that would be the ultimate win–win situation.

Dealing with data, information, and knowledge: from hype to hope?

Despite massive efforts in the design of tools, databases, robotic techniques, and management innovations, luck seems to be at the basis of the discovery of most new medicines [197]. The blockbuster Viagra is probably the best illustration of the opportunism that we tend to call serendipity [198].

In 1997, i.e., long before the first GPCR structure became available, Kuipers et al. [199] performed a massive literature search for aryloxypropanolamines and similar compounds binding to the serotonin 5HT-1a receptor and a series of sequence similar amine receptors. A correlation analysis [200] revealed that only one residue’s presence/absence showed a perfect correlation with binding/non-binding of a series of compounds. A mutational study validated the hypothesis that this correlation indicated a direct hydrogen bond between an alcohol group in the aminergic ligand and asparagine 719 [201]. When the structure of the human β2 adrenoceptor bound to carazolol was solved by X-ray [PDBid 2RH1; 202], it showed indeed two hydrogen bonds between Asn-719 and this similar ligand (see Fig 4). By the way, in none of the GPCR homology models available in 199×, did Asn-719 interact with a ligand.

In another GPCR related project aimed at using as much heterogeneous data as can possibly be combined, Oliveira et al. [203] predicted the role of all ‘active site’ residues in GPCRs, the pivotal role of Arg-340 [204], and even a series of residue interactions involved in the activation process, and the presence and location of helix VIII [205]. The recent flurry of articles on GPCR Xray structures [206209], and especially the structure with a covalently agonist-bound G protein [210] showed all these predictions to be conceptually right.

These two GPCR-related examples make clear that there is a lot to be gained from using experimental data. But these examples also taught us how hard it is to actually get access to those data. With the GPCRDB [211213] we have started a trend to make Molecular Class Specific Information Systems (MCSIS). And a small company, Bio-Prodict ( recently caught on and is now making MCSISes for a wide variety of commercially interesting molecules [214218]. Their systems (some of which are freely accessible from their website) revolve around a structure based, and thus very accurate multiple sequence alignment (MSA) for a whole protein super-family. This MSA then functions as the anchor on which to position all kinds of data that can range from 3D structures to genome related data, from mutation studies to ligand binding constants, or from sequence correlation patterns to the prediction of mutations that enhance the protein’s stability. As the most powerful information tends to be carefully hidden in the literature, an extensive set of literature-mining scripts aids with the extraction of, for example, mutation information. In fact, it was shown that the suite of mutation data extracting scripts reaches a much better coverage than can be obtained by human experts [214218].

A recent development that will aid the drug hunters of the future is the Utopia PDF reader [213, 219]. Vroling et al. [213] showed how this programmable PDF reader could be used to directly couple data in articles on GPCRs to the GPCRDB. This intelligent hyperlinking has a series of benefits. First, the residue numbering problem gets solved because the reader can ask the GPCRDB for the position in the GPCR MSA of any residue mentioned in the article, and it can even modify or correct the sequence numbers in the article if needed. Much good GPCR mutation data was published in the pre-GPCR-structure era that ended with the opsin structure article [220], and often these data were misinterpreted because of the poor quality of the available homology models [221]. The Utopia-GPCR PDF reader can correct those interpretations thereby salvaging old, high quality experimental data for future use. Figure 5 shows an image from an old mutation study [222] in which the authors describe several ground-breaking mutations in the guinea pig histamine H1 receptor, building and validating a homology model using these data, and arguing, for example, that residue Trp161 plays an important role in receptor-ligand binding. This assumption was based on the effect of the mutation on receptor function, leading to a model in which Trp161 was modelled in the ligand-binding site. By contrast, the GPCRDB generated annotation listed in the sidebar of the reader indicates that this residue, located in TM IV, points towards the membrane and possibly interacts with cholesterol. This is a completely different situation from that proposed by the authors. Looking at the model provided by the GPCRDB, based on the latest crystal structures, it can be seen that a direct role of Trp161 in receptor-ligand binding is highly unlikely.

Folkerstma et al. (2005) analyzed nearly 100 nuclear receptor (NR) ligand binding domains. Combined with manually curated multiple sequence alignments, key positions in the ligand binding pocket were identified that had specific interactions with functionally diverse compounds. For example, residues at position 26 in Fig. 6 were shown to only have interactions with antagonists. This analysis required a substantial amount of work: categorizing structures and compounds, creating multiple sequence alignments, analyzing ligand contacts, and transferring the results into a homogeneous residue numbering scheme (the so-called 3D numbers). With the 3DM information system [223; see the help movie], these analyses can today be performed in a matter of minutes [215, 217, 224].

More than 100 articles were found that discuss the effects of mutating this residue on the ligand binding of the receptor. In all these articles this same residue has 14 different residue numbers ranging from 52 to 709. The use of a common 3D numbering scheme enables transfer of heterogeneous information between protein family members. Figure 7 shows 40 antagonists in red and 70 agonists in blue. In this example, a hundred articles had to be ‘read’ to extract all available mutation information for this single position mutated in 22 different receptor—species combinations. That these 100 articles had to be found among 100,000 PubMed entries that contain NR information is a whole different story in itself.

If, one day, all structures of NR-ligand complexes that now are scattered over inaccessible industrial hard disks could be concentrated in one system, then we could consider asking much more elaborate questions. We could consider correlating aspects of ligands with protein atom characteristics, or we could analyse if residues not contacting the ligand have an influence on binding or activation, etcetera.

It is not only important to get as much information as possible stored in systems amenable to scrutiny, but it is also important to realize that for every one bioinformatician or drug hunter there are one hundred scientists who do not use molecular software regularly. Project Hope aims to predict the molecular phenotype of point mutations that were shown causally related to human disease states [225]. This system attempts in all stages of user interaction to cater for human geneticists who typically do not use molecular software at all. Hope only asks the user to cut-n-paste the sequence, and click the residue mutated and the mutation residue type. It then builds a homology model if needed, calls dozens of servers and services in seven countries, combines all possible information and writes a final report that can be directly used in publications, but, more importantly, that is written without using any bioinformatics jargon and even has a build-in dictionary that explains terms such as ‘active site’, ‘salt-bridge’, or ‘torsion angle’ in human genetics understandable terms. Hope thus is the ultimate translation machine because in doing translational research it even translates between the researchers.

We believe that the recent spate of consolidations in the pharmaceutical industry is not a problem but an opportunity. Mankind needs medicines, and now that pushing ones luck is slowly becoming a less successful technique, only research can find them. This research can progress rapidly if the thousands and thousands of X-ray structures of protein–ligand complexes would find their way from hard-disks behind pharmaceutical industry firewalls to the public domain. Drug design research in the next 25 years will revolve around ever broader collaborations, ever more holistic understanding of the drug—human interactions, and ever better use of the available data, information, and knowledge.

VL and GV acknowledge financial support from NBIC, and TIPharma, TvdB appreciate the support from Bio-Prodict ( The authors thank Jan Kelder for critically reviewing the manuscript. Elmar Krieger helped with YASARA, Maarten Hekkelman, Coos Baakman, Bas Vroling, Wilmar Teunissen, Barbara van Kampen, provided technical support. The authors mention with pleasure the many stimulating discussions with Sander Nabuurs, Daniel Gironés, Gijs Schaftenaar, Friedrich Rippmann, Ad IJzerman, Margot Beukers, Isabel Duarte, Christof Francke, Henk-Jan Joosten, Jacob de Vlieg.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

1.. Life expectancy (2011) Accessed 6 Dec 2011
2.. World War I casualties (2011) Accessed 6 Dec 2011
3.. Medecine and World War II (2011) Accessed 16 Feb 2011
4.. Snell ES,Griffin JP. How many medicines are there?Br Med JYear: 19852907737743918749
5.. Lewington A. Medicinal plants and plant extracts: a review of the importation into Europe. Traffic network reportYear: 1993Cambridge, UKTraffic International
6.. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov. doi:10.1038/nrd2199
7.. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. doi:10.1038/nrd2961
8.. Troubled Asset Relief Program (2011) Accessed 6 Dec 2011
9.. Firestone RA (2011) Lessons from 54 years of pharmaceutical research Nat Rev Drug Discov. doi:10.1038/nrd2961-c1
10.. Robert B, Matthew T, Sean H, Bernard B (2000) Drug design by machine learning: support vector machine for pharmaceutical data analysis. Proceedings of the AISB’00 symposium on artificial intelligence in bioinformatics. pp 1–4
11.. Byvatov E,Fechner U,Sadowski J,Schneider G. Comparison of support vector machine and artificial neural network systems for drug/nondrug classificationJ Chem Inf Comput SciYear: 2003431882188914632437
12.. Gagnon MA, Lexchin J (2008) The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. doi:10.1371/journal.pmed.0050001
13.. Hol WGJ. Protein crystallography and computer-graphics toward rational drug designAngew Chem Int Ed EnglYear: 198625767778
14.. Bolin JT,Filman DJ,Matthews DA,Hamlin RC,Kraut J. Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexateJ Biol ChemYear: 198225713663136726815179
15.. Thompson PE,Manallack DT,Blaney FE,Gallagher T. Conformational studies on (+)-anatoxin-a and derivativesJ Comput Aided Mol DesYear: 199262872981517779
16.. Ruiz J,López M,Milà J,Lozoya E,Lozano JJ,Pouplana R. QSAR and conformational analysis of the antiinflammatory agent amfenac and analoguesJ Comput Aided Mol DesYear: 199371831988320556
17.. Aleman C,Perez JJ. SCF-MO study of the polyglycine II structureJ Comput Aided Mol DesYear: 1993722412508320559
18.. Oyasu H,Nakanishi I,Tanaka A,Murano K,Matsuo M. Conformational studies on the four stereoisomers of the novel anticholinergic 4-(dimethylamino)-2-phenyl-2-(2-pyridyl)pentanamideJ Comput Aided Mol DesYear: 199591711807608748
19.. Schaftenaar G,Noordik JH. Molden: a pre- and post-processing program for molecular and electronic structuresJ Comput Aided Mol DesYear: 20001412313410721501
20.. Manzetti S,McCulloch DR,Herington AC,Spoel D. Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10J Comput Aided Mol DesYear: 20031755156514713188
21.. Duran D,Aviyente V,Baysa C. Solvent effect on the synthesis of clarithromycin: a molecular dynamics studyJ Comput Aided Mol DesYear: 20041814515415287700
22.. Curioni A,Mordasini T,Andreoni W. Enhancing the accuracy of virtual screening: molecular dynamics with quantum-refined force fieldsJ Comput Aided Mol DesYear: 20041877378416075309
23.. Hammond PS,Wu Y,Harris R,Minehardt TJ,Car R,Schmitt JD. Protonation-induced stereoisomerism in nicotine: conformational studies using classical (AMBER) and ab initio (Car-Parrinello) molecular dynamicsJ Comput Aided Mol DesYear: 20051911516059663
24.. Roccatano D,Sbardella G,Aschi M,Amicosante G,Bossa C,Nola AD,Mazza F. Dynamical aspects of TEM-1 beta-lactamase probed by molecular dynamicsJ Comput Aided Mol DesYear: 20051932934016184435
25.. Chipot C,Rozanska X,Dixit SB. Can free energy calculations be fast and accurate at the same time? Binding of low-affinity, non-peptide inhibitors to the SH2 domain of the src proteinJ Comput Aided Mol DesYear: 20051976577016365699
26.. Fanelli F,Benedetti PG. Inactive and active states and supramolecular organization of GPCRs: insights from computational modelingJ Comput Aided Mol DesYear: 20062044946117009093
27.. Bharatham K,Bharatham N,Kwon YJ,Lee KW. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modelingJ Comput Aided Mol DesYear: 20082292593318685809
28.. Eyrisch S,Helms V. What induces pocket openings on protein surface patches involved in protein-protein interactions?J Comput Aided Mol DesYear: 200923738618777159
29.. Gunsteren WF,Berendsen HJ. Thermodynamic cycle integration by computer simulation as a tool for obtaining free energy differences in molecular chemistryJ Comput Aided Mol DesYear: 198711711763504214
30.. Hansson T,Marelius J,Aqvist J. Ligand binding affinity prediction by linear interaction energy methodsJ Comput Aided Mol DesYear: 19981227359570087
31.. Wilcox GL,Quiocho FA,Levinthal C,Harvey SC,Maggiora GM,McCammon JA. Symposium overview. Minnesota conference on supercomputing in biology: proteins, nucleic acids, and waterJ Comput Aided Mol DesYear: 198812712813193133
32.. Wimmer E. Future in biomolecular computationJ Comput Aided Mol DesYear: 198812832903193134
33.. Allinger NL. Conformational-analysis. 130. Mm2—hydrocarbon force-field utilizing V1 and V2 torsional termsJ Am Chem SocYear: 19779981278134
34.. Stewart JJP. Special issue—Mopac—a semiempirical molecular-orbital programJ Comput Aided Mol DesYear: 199041452197373
35.. Allen FH,Harris SE,Taylor R. Comparison of conformer distributions in the crystalline state with conformational energies calculated by ab initio techniquesJ Comput Aided Mol DesYear: 1996102472548808740
36.. Klebe G,Mietzner T. A fast and efficient method to generate biologically relevant conformationsJ Comput Aided Mol DesYear: 199485836067876902
37.. Bostrom J,Norrby PO,Liljefors T. Conformational energy penalties of protein-bound ligandsJ Comput Aided Mol DesYear: 1998123833969777496
38.. Mayer D,Naylor CB,Motoc I,Marshall GR. A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studiesJ Comput Aided Mol DesYear: 198713162851035
39.. Martin J,Andrews P. Conformation-activity relationships of opiate analgesicsJ Comput Aided Mol DesYear: 1987153722905731
40.. Martin YC,Bures MG,Danaher EA,DeLazzer J,Lico I,Pavlik PA. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonistsJ Comput Aided Mol DesYear: 19937831028097240
41.. Lakdawala A, Wang M, Nevins N, Liotta D, Rusinska-Roszak D, Lozynski M, Snyder JP (2001) Calculated conformer energies for organic molecules with multiple polar functionalities are method dependent: taxol (case study). BMC Chem Biol. doi:10.1186/1472-6769-1-2
42.. Vieth M, Hirst JD, Brooks CL (1998) Do active site conformations of small ligands correspond to low free-energy solution structures? J Comput Aided Mol Des 12:563–572
43.. Klebe G. Toward a more efficient handling of conformational flexibility in computer-assisted modelling of drug moleculesPerspect Drug Discov DesYear: 1995385105
44.. Ota N,Agard DA. Binding mode prediction for a flexible ligand in a flexible pocket using multi-conformation simulated annealing pseudo crystallographic refinementJ Mol BiolYear: 200131460761711846570
45.. Diller DJ,Merz KM Jr. Can we separate active from inactive conformations?J Comput Aided Mol DesYear: 20021610511212188020
46.. Huse M,Kuriyan J. The conformational plasticity of protein kinasesCellYear: 200310927528212015977
47.. Teague SJ. Implications of protein flexibility for drug discoveryNat Rev Drug DiscovYear: 2003252754112838268
48.. Chouard T. Structural biology: breaking the protein rulesNatureYear: 200547115115321390105
49.. Dyson HJ,Wright PE. Intrinsically unstructured proteins and their functionsNatl Rev Mol Cell BiolYear: 20056197208
50.. Uversky VN,Dunker AK. Understanding protein non-foldingBiochim Biophys ActaYear: 201018041231126420117254
51.. Kuntz ID,Blaney JM,Oatley SJ,Langridge R,Ferrin TE. A geometric approach to macromolecule-ligand interactionsJ Mol BiolYear: 19821612692887154081
52.. Bohm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structureJ Comput Aided Mol DesYear: 199482432567964925
53.. Meng EC,Kuntz ID,Abraham DJ,Kellogg GE. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicitiesJ Comput Aided Mol DesYear: 199482993067964929
54.. Jain AN. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinitiesJ Comput Aided Mol DesYear: 1996104274408951652
55.. Wang R,Lai L,Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity predictionJ Comput Aided Mol DesYear: 200216112612197663
56.. Kelly MD,Mancera RL. A new method for estimating the importance of hydrogen-bonding groups in the binding site of a proteinJ Comput Aided Mol DesYear: 20031740141414677637
57.. Muryshev AE,Tarasov DN,Butygin AV,Butygina OY,Aleksandrov AB,Nikitin SM. A novel scoring function for molecular dockingJ Comput Aided Mol DesYear: 20031759760514713191
58.. Morley SD,Afshar M. Validation of an empirical RNA-ligand scoring function for fast flexible docking using RibodockJ Comput Aided Mol DesYear: 20041818920815368919
59.. Tame JR. Scoring functions—the first 100 yearsJ Comput Aided Mol DesYear: 20051944545116231202
60.. Jain AN. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based searchJ Comput Aided Mol DesYear: 20092128130617387436
61.. Cincilla G,Vidal D,Pons M. An improved scoring function for suboptimal polar ligand complexesJ Comput Aided Mol DesYear: 20092314315218843450
62.. Dobeš P,Fanfrlík J,Rezáč J,Otyepka M,Hobza P. Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitorsJ Comput Aided Mol DesYear: 201125322323521286784
63.. Tondel K,Anderssen E,Drablos F. Protein alpha shape (PAS) dock: a new gaussian-based score function suitable for docking in homology modelled protein structuresJ Comput Aided Mol DesYear: 20062013114416652207
64.. Miller MD,Kearsley SK,Underwood DJ,Sheridan RP. FLOG: a system to select ‘quasi-flexible’ ligands complementary to a receptor of known three-dimensional structureJ Comput Aided Mol DesYear: 199481531748064332
65.. Kearsley SK, Underwood DJ, Sheridan RP, Miller MD Flexibases: a way to enhance the use of molecular docking methods. J Comput Aided Mol Des 8:565–582
66.. Oshiro CM,Kuntz ID,Dixon JS. Flexible ligand docking using a genetic algorithmJ Comput Aided Mol DesYear: 199591131307608743
67.. Knegtel RM, Bayada DM, Engh RA, von der Saal W, van Geerestein VJ, Grootenhuis PD Comparison of two implementations of the incremental construction algorithm in flexible docking of thrombin inhibitors. J Comput Aided Mol Des 13:167–183
68.. Makino S,Ewing TJ,Kuntz ID. DREAM++: flexible docking program for virtual combinatorial librariesJ Comput Aided Mol DesYear: 19991351353210483532
69.. Ewing TJ,Makino S,Skillman AG,Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databasesJ Comput Aided Mol DesYear: 20011541142811394736
70.. Hindle SA,Rarey M,Buning C,Lengaue T. Flexible docking under pharmacophore type constraintsJ Comput Aided Mol DesYear: 20021612914912188022
71.. Grasselli M,Cascone O,Birger Anspach F,Delfino JM. On the molecular interaction between lactoferrin and the dye Red HE-3b. A novel approach for docking a charged and highly flexible molecule to protein surfacesJ Comput Aided Mol DesYear: 20021691793412825623
72.. Bursulaya BD,Totrov M,Abagyan R,Brooks CL 3rd. Comparative study of several algorithms for flexible ligand dockingJ Comput Aided Mol DesYear: 20031775576315072435
73.. Bottegoni G,Kufareva I,Totrov M,Abagyan R. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE)J Comput Aided Mol DesYear: 20082231132518273556
74.. Zhao Y,Sanner MF. Protein-ligand docking with multiple flexible side chainsJ Comput Aided Mol DesYear: 20082267367918034309
75.. Kang L,Li H,Jiang H,Wang X. An improved adaptive genetic algorithm for protein-ligand dockingJ Comput Aided Mol DesYear: 20092311218777161
76.. Jain AN. Effects of protein conformation in docking: improved pose prediction through protein pocket adaptationJ Comput Aided Mol DesYear: 20092335537419340588
77.. Garden DP,Zhorov BS. Docking flexible ligands in proteins with a solvent exposure- and distance-dependent dielectric functionJ Comput Aided Mol DesYear: 2010249110520119653
78.. Totrov M,Abagyan R. Flexible ligand docking to multiple receptor conformations: a practical alternativeCurr Opin Struct BiolYear: 20081817818418302984
79.. Bohm HJ,Klebe G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs?Angew Chem Int Ed EnglYear: 19963525892614
80.. Shoichet BK,Leach AR,Kuntz ID. Ligand solvation in molecular dockingProtein Sruct Funct GenetYear: 199934416
81.. Gohlke H,Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptorsAngew Chem Int EdYear: 20024126442676
82.. Demchuk E,Wade RC. Improving the continuum dielectric approach to calculating pK(a)s of ionizable groups in proteinsJ Phys ChemYear: 19961001737317387
83.. Nielsen JE,Vriend G. Optimizing the hydrogen-bond network in Poisson-Boltzmann equation-based pK(a) calculationsProtein Stuct Funct GenetYear: 200143403412
84.. Rarey M,Kramer B,Lengauer T,Klebe G. A fast flexible docking method using an incremental construction algorithmJ Mol BiolYear: 19962614704898780787
85.. Goodsell DS,Morris GM,Olson AJ. Automated docking of flexible ligands: applications of AutoDockJ Mol RecognitYear: 19969158723313
86.. Friesner RA,Banks JL,Murphy RB,Halgren TA,Klicic JJ,Mainz DT,Repasky MP,Knoll EH,Shelley M,Perry JK,Shaw DE,Francis P,Shenkin PS. A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracyJ Med ChemYear: 2004471739174915027865
87.. Jones G,Willett P,Glen RC,Leach AR,Taylor R. Development and validation of a genetic algorithm for flexible dockingJ Mol BiolYear: 19972677277489126849
88.. Hartmann C,Antes I,Lengauer T. Docking and scoring with alternative side-chain conformationsProteinsYear: 20097471272618704939
89.. Taylor RD,Jewsbury PJ,Essex JW. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy functionJ Comput ChemYear: 2003241637165612926007
90.. Muegge I. PMF scoring revisitedJ Med ChemYear: 2006495895590217004705
91.. Englebienne P,Moitessier N. Docking ligands into flexible and solvated macromolecules. 4. Are popular scoring functions accurate for this class of proteins?J Chem Inf ModelYear: 2009491568158019445499
92.. Oda A,Tsuchida K,Takakura T,Yamaotsu N,Hirono S. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexesJ Chem Inf ModelYear: 20064638039116426072
93.. Foloppe N,Hubbard R. Towards predictive ligand design with free-energy based computational methods?Curr Med ChemYear: 2006133583360817168725
94.. Jain AN. Scoring functions for protein-ligand dockingCurr Protein Pept SciYear: 2006740742017073693
95.. Robertson TA,Varani G. An all-atom, distance-dependent scoring function for the prediction of protein-DNA interactions from structureProteinsYear: 20076635937417078093
96.. Rajamani R,Good AC. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function developmentCurr Opin Drug Discov DevelYear: 200710308315
97.. Tembre BL,McCammon JA. Ligand-receptor interactionsComput ChemYear: 19848281283
98.. Ferguson DM,Radmer RJ,Kollman PA. Determination of the relative binding free-energies of peptide inhibitors to the Hiv-1 proteaseJ Med ChemYear: 199134265426591652028
99.. Cramer RD,Patterson DE,Bunce JD. Comparative molecular-field analysis (Comfa).1. Effect of shape on binding of steroids to carrier proteinsJ Am Chem SocYear: 19881105959596722148765
100.. Norinder U. Experimental design based 3-D QSAR analysis of steroid-protein interactions: application to human CBG complexesJ Comput Aided Mol DesYear: 199043813892092083
101.. Bursi R,Grootenhuis PD. Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexesJ Comput Aided Mol DesYear: 19991322123210216830
102.. Zhang Z,An L,Hu W,Xiang Y. 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approachJ Comput Aided Mol DesYear: 20072114515317203365
103.. Cramer RD, Milne M (1979) Lattice model–general paradigm for shape-related structure-activity correlation. Abstracts of papers of the American chemical society, 19th ACS Meeting COMP 44
104.. Nicklaus MC,Milne GW,Burke TR Jr. QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitorsJ Comput Aided Mol DesYear: 199264875041474396
105.. Rault S,Bureau R,Pilo JC,Robba M. Comparative molecular field analysis of CCK-A antagonists using field-fit as an alignment technique. A convenient guide to design new CCK-A ligandsJ Comput Aided Mol DesYear: 199265535681291625
106.. Calder JA,Wyatt JA,Frenkel DA,Casida JE. CoMFA validation of the superposition of six classes of compounds which block GABA receptors non-competitivelyJ Comput Aided Mol DesYear: 1993745608386230
107.. Kroemer RT,Hecht P. A new procedure for improving the predictiveness of CoMFA models and its application to a set of dihydrofolate reductase inhibitorsJ Comput Aided Mol DesYear: 199593964068594157
108.. Gohda K,Mori I,Ohta D,Kikuchi T. A CoMFA analysis with conformational propensity: an attempt to analyze the SAR of a set of molecules with different conformational flexibility using a 3D-QSAR methodJ Comput Aided Mol DesYear: 20001426527510756481
109.. Manchester J,Czermiński R. CAUTION: popular “Benchmark” data sets do not distinguish the merits of 3D QSAR methodsJ Chem Inf ModelYear: 2009491449145419438212
110.. Kharkar PS,Reith ME,Dutta AK. Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitorsJ Comput Aided Mol DesYear: 20082211718060532
111.. Park H,Lee S. Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitorsJ Comput Aided Mol DesYear: 20041837538815662999
112.. Tomich CH,da Silva P,Carvalho I,Taft CA. Homology modeling and molecular interaction field studies of alpha-glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitorsJ Comput Aided Mol DesYear: 200519839216075303
113.. Rossi KA,Markwalder JA,Seitz SP,Chang CH,Cox S,Boisclair MD,Brizuela L,Brenner SL,Stouten PF. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitorsJ Comput Aided Mol DesYear: 20051911112216075305
114.. Schlegel B,Laggner C,Meier R,Langer T,Schnell D,Seifert R,Stark H,Höltje HD,Sippl W. Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screeningJ Comput Aided Mol DesYear: 20072143745317668276
115.. Katritch V,Byrd CM,Tseitin V,Dai D,Raush E,Totrov M,Abagyan R,Jordan R,Hruby DE. Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approachesJ Comput Aided Mol DesYear: 20072154955817960327
116.. Neves MA,Simoes S,Sa e Melo ML. Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approachJ Comput Aided Mol DesYear: 2010241023103320960031
117.. Knehans T,Schüller A,Doan DN,Nacro K,Hill J,Güntert P,Madhusudhan MS,Weil T,Vasudevan SG. Structure-guided fragment-based in silico drug design of dengue protease inhibitorsJ Comput Aided Mol DesYear: 20112526327421344277
118.. Eberini I,Daniele S,Parravicini C,Sensi C,Trincavelli ML,Martini C,Abbracchio MP. In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseasesJ Comput Aided Mol DesYear: 20112574375221744154
119.. Sali A,Blundell TL. Comparative protein modelling by statisfaction of spatial restraintsJ Mol BiolYear: 19932347798158254673
120.. Vriend G (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph 8:52–56
121.. Reichelt J, Dieterich G, Kvesic M, Schomburg D, Heinz DW (2005) BRAGI: linking and visualization of database information in a 3D viewer and modeling tool. Bioinformatics 21:1291–1293
122.. Krieger E,Joo K,Lee J,Lee J,Raman S,Thompson J,Tyka M,Baker D,Karplus K. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8ProteinsYear: 2009911412219768677
123.. Thompson J,Baker D. Incorporation of evolutionary information into Rosetta comparative modelingProtein Struct Func BioinfoYear: 20117923802388
124.. CASP1 proceedingsProtein Struct Funct GenetYear: 199523295460
125.. Harris MR,Kihlen M,Bywater RP. PLIM: a protein-ligand interaction modellerJ Mol RecognitYear: 199361111158060668
126.. Michino M, Abola E; GPCR Dock 2008 participants, Brooks CL 3rd, Dixon JS, Moult J, Stevens RC (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 Nat Rev Drug Discov 8:455–463
127.. Kufareva I, Rueda M, Vsevolod K, Stevens RC, Abagyan R, GPCR Dock 2010 participants Status of GPCR modeling and docking as reflected by community wide GPCR Dock 2010 assessment. Structure 19:1108–1126
128.. Broer BM,Gurrath M,Holtje HD. Molecular modelling studies on the ORL1-receptor and ORL1-agonistsJ Comput Aided Mol DesYear: 20031773975415072434
129.. Miguet L,Zhang Z,Barbier M,Grigorov MG. Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitorsJ Comput Aided Mol DesYear: 200620678116783599
130.. Roumen L,Sanders MP,Vroling B,Esch IJ,Vlieg J,Leurs R,Klomp JP,Nabuurs SB,Graaf C. The pitfalls and challenges of predicting GPCR-ligand interactionsPharmaceuticalsYear: 2011411961215
131.. Henriques ES,Floriano WB,Reuter N,Melo A,Brown D,Gomes JA,Maigret B,Nascimento MA,Ramos MJ. The search for a new model structure of beta-factor XIIaJ Comput Aided Mol DesYear: 20011530932211349814
132.. Brown N,McKay B,Gasteiger J. The de novo design of median molecules within a property range of interestJ Comput Aided Mol DesYear: 20041876177116075308
133.. Belda I, Madurga S, Llorà X, Martinell M, Tarragó T, Piqueras MG, Nicolás E, Giralt E (2005) ENPDA: an evolutionary structure-based de novo peptide design algorithm. J Comput Aided Mol Des 19:585–601
134.. Zaliani A et al (2009) Second-generation de novo design: a view from a medicinal chemist perspective. J Comput Aided Mol Des
135.. Goodford PJ. A computational-procedure for determining energetically favorable binding-sites on biologically important macromoleculesJ Med ChemYear: 1985288498573892003
136.. Wade RC,Clark KJ,Goodford PJ. Further development of hydrogen-bond functions for use in determining energetically favorable binding-sites on molecules of known structure.1. Ligand probe groups with the ability to form 2 hydrogen-bondsJ Med ChemYear: 1993361401478421280
137.. Rotstein SH,Murcko MA. GroupBuild: a fragment-based method for de novo drug designJ Med ChemYear: 199336170017108510098
138.. Willett P. Genetic algorithms in molecular recognition and designTrends BiotechnolYear: 1995135165218595137
139.. Bohm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitorsJ Comput Aided Mol DesYear: 1992661781583540
140.. Bohm HJ. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leadsJ Comput Aided Mol DesYear: 199265936061291628
141.. Clark DE,Frenkel D,Levy SA,Li J,Murray CW,Robson B,Waszkowycz B,Westhead DR. PRO-LIGAND: an approach to de novo molecular design. 1. Application to the design of organic moleculesJ Comput Aided Mol DesYear: 1995913327751867
142.. Westhead DR, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Waszkowycz B (1995) PRO-LIGAND: an approach to de novo molecular design. 3. A genetic algorithm for structure refinement. J Comput Aided Mol Des 9:139–148
143.. Rarey M,Wefing S,Lengauer T. Placement of medium-sized molecular fragments into active sites of proteinsJ Comput Aided Mol DesYear: 19961041548786414
144.. Barakat MT,Dean PM. The atom assignment problem in automated de novo drug design. 1. Transferability of molecular fragment propertiesJ Comput Aided Mol DesYear: 199593413508523043
145.. Rotstein SH,Murcko MA. GenStar: a method for de novo drug designJ Comput Aided Mol DesYear: 1993723438473916
146.. Roe DC,Kuntz ID. BUILDER v.2: improving the chemistry of a de novo design strategyJ Comput Aided Mol DesYear: 199592692827561978
147.. Leach AR,Kilvington SR. Automated molecular design: a new fragment-joining algorithmJ Comput Aided Mol DesYear: 199482832987964928
148.. Golberg DE. Genetic algorithms in search, optimization and machine learningYear: 1989New YorkAddison-Wesley
149.. Todorov NP,Dean PM. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand designJ Comput Aided Mol DesYear: 1997111751929089435
150.. Schneider G,Lee ML,Stahl M,Schneider P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocksJ Comput Aided Mol DesYear: 20001448749410896320
151.. Blum LC,Reymond JL. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13J Am Chem SocYear: 20091318732873319505099
152.. Kubinyi H. HTS technologies—IBC informa conferenceIDrugsYear: 1992416817316032477
153.. Sudarsanam S,Virca GD,March CJ,Srinivasan S. An approach to computer-aided inhibitor design: application to cathepsin LJ Comput Aided Mol DesYear: 199262232331517775
154.. Bohm HJ,Banner DW,Weber L. Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitorsJ Comput Aided Mol DesYear: 199913515610087499
155.. Filikov AV,Mohan V,Vickers TA,Griffey RH,Cook PD,Abagyan RA,James TL. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TARJ Comput Aided Mol DesYear: 20001459361010921774
156.. Furet P,Meyer T,Mittl P,Fretz H. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searchingJ Comput Aided Mol DesYear: 20011548949511394741
157.. Afantitis A,Melagraki G,Sarimveis H,Koutentis PA,Markopoulos J,Igglessi-Markopoulou O. Investigation of substituent effect of 1-(3, 3-diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniquesJ Comput Aided Mol DesYear: 200620839516783600
158.. Kortagere S,Welsh WJ. Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptorsJ Comput Aided Mol DesYear: 20062078980217054015
159.. Talevi A,Bellera CL,Castro EA,Bruno-Blanch LE. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparabenJ Comput Aided Mol DesYear: 20072152753817960329
160.. Irwin JJ. Community benchmarks for virtual screeningJ Comput Aided Mol DesYear: 20082219319918273555
161.. Krueger BA,Weil T,Schneider G. Comparative virtual screening and novelty detection for NMDA-GlycineB antagonistsJ Comput Aided Mol DesYear: 20092386988119890609
162.. Didziapetris R,Dapkunas J,Sazonovas A,Japertas P. Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibitionJ Comput Aided Mol DesYear: 20102489190620814717
163.. Joseph-McCarthy D (2002) An overview of in silico design and screening: toward efficient drug discovery. Curr Drug Discov 20–23
164.. Bajorath J. Virtual screening: methods, expectations, and realityCurr Opin Drug Discov DevYear: 200222428
165.. Rarey M,Stahl M. Similarity searching in large combinatorial chemistry spacesJ Comput Aided Mol DesYear: 20011549752011495223
166.. Hopkins AL,Groom CR,Alex A. Ligand efficiency: a useful metric for lead selectionDrug Discov TodayYear: 2004943043115109945
167.. Abad-Zapatero C,Metz JT. Ligand efficiency indices as guideposts for drug discoveryDrug Discov TodayYear: 20051046446915809192
168.. Jain AN,Koile K,Chapman D. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmarkJ Med ChemYear: 199437231523278057280
169.. Handschuh S,Goldfuss B,Chen J,Gasteiger J,Houk KN. Steroid binding by antibodies and artificial receptors: exploration of theoretical methods to determine the origins of binding affinities and specificitiesJ Comput Aided Mol DesYear: 20001461162911008884
170.. Jain AN,Dietterich TG,Lathrop RH,Chapman D,Critchlow RE Jr,Bauer BE,Webster TA,Lozano-Perez T. A shape-based machine learning tool for drug designJ Comput Aided Mol DesYear: 199486356527738601
171.. Walters WP,Murcko MA. Prediction of ‘drug-likeness’Adv Drug Deliv RevYear: 20025425527111922947
172.. Jung E,Choi SH,Lee NK,Kang SK,Choi YJ,Shin JM,Choi K,Jung DH. Machine learning study for the prediction of transdermal peptideJ Comput Aided Mol DesYear: 20112533934721448715
173.. Sapre NS,Gupta S,Pancholi N,Sapre N. Molecular docking studies on tetrahydroimidazo-[4, 5, 1-jk][1, 4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitorsJ Comput Aided Mol DesYear: 200822698018163186
174.. Hirst JD,King RD,Sternberg MJ. Quantitative structure-activity relationships by neural networks and inductive logic programming. II. The inhibition of dihydrofolate reductase by triazinesJ Comput Aided Mol DesYear: 199484214327815093
175.. Livingstone DJ,Manallack DT,Tetko IV. Data modelling with neural networks: advantages and limitationsJ Comput Aided Mol DesYear: 1997111351429089431
176.. Doweyko AM. QSAR: dead or alive?J Comput Aided Mol DesYear: 200822818918189157
177.. Che Y,Brooks BR,Marshall GR. Development of small molecules designed to modulate protein-protein interactionsJ Comput Aided Mol DesYear: 20062010913016622794
178.. Lotta T,Taskinen J,Bäckström R,Nissinen E. PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitorsJ Comput Aided Mol DesYear: 199262532721517777
179.. Zhou H, Lai WP, Zhang Z, Li WK, Cheung HY (2009) Computational study on the molecular inclusion of andrographolide by cyclodextrin. J Comput Aided Mol Des 23:153–162
180.. Sarmah P,Deka RC. DFT-based QSAR and QSPR models of several cis-platinum complexes: solvent effectJ Comput Aided Mol DesYear: 20092334335419308327
181.. Singh N,Chevé G,Ferguson DM,McCurdy CR. A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonistJ Comput Aided Mol DesYear: 20062047149317009091
182.. Zheng M,Yu K,Liu H,Luo X,Chen K,Zhu W,Jiang H. QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSARJ Comput Aided Mol DesYear: 20062054956617103017
183.. Clark RD. A ligand’s-eye view of protein bindingJ Comput Aided Mol DesYear: 20082250752118217215
184.. Caballero J,Quiliano M,Alzate-Morales JH,Zimic M,Deharo E. Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2, 1-f][1, 2, 4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2, 3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitorsJ Comput Aided Mol DesYear: 20112534936921487786
185.. Yoo J,Medina-Franco JL. Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferaseJ Comput Aided Mol DesYear: 20112555556721660514
186.. Papp B,Notebaart RA,Pál C. Systems-biology approaches for predicting genomic evolutionNat Rev GenetYear: 20111259160221808261
187.. Breimer DD. PK/PD modelling and beyond: impact on drug developmentPharm ResYear: 2008252720272218810328
188.. Swati Chaturvedi Outsourcing in Pharmaceutical Industry (2011) Accessed 6 Dec 2011
189.. Protein Data Bank (2011) Accessed 6 Dec 2011
190.. Berman HM,Westbrook J,Feng Z,Gilliland G,Bhat TN,Weissig H,Shindyalov IN,Bourne PE. The protein data bankNucleic Acids ResYear: 20002823524210592235
191.. Read RJ,Adams PD,Arendall WB 3rd,Brunger AT,Emsley P,Joosten RP,Kleywegt GJ,Krissinel EB,Lütteke T,Otwinowski Z,Perrakis A,Richardson JS,Sheffler WH,Smith JL,Tickle IJ,Vriend G,Zwart PH. A new generation of crystallographic validation tools for the protein data bankStructureYear: 2011191395141222000512
192.. PDB redo (2011) Accessed 29 Nov 2011
193.. Joosten RP,Vriend G. PDB improvement starts with data depositionScienceYear: 200731719519617626865
194.. Joosten RP, Joosten K, Cohen SX, Vriend G, Perrakis A (2011) Automatic rebuilding and optimization of crystallographic structures in the PDB. Bioinformatics Epub ahead of print
195.. Joosten RP,Salzemann J,Bloch V,Stockinger H,Berglund A,Blanchet C,Bongcam-Rudloff E,Combet C,Da Costa AL,Deleage G,Diarena M,Fabbretti R,Fettahi G,Flegel V,Gisel A,Kasam V,Kervinen T,Korpelainen E,Mattila K,Pagni M,Reichstadt M,Breton V,Tickle IJ,Vriend G. PDB_REDO: automated re-refinement of X-ray structure models in the PDBJ Appl CrystYear: 200942376384
196.. Joosten RP,Womack T,Vriend G,Bricogne G. Re-refinement from deposited X-ray data can deliver improved models for most PDB entriesActa Crystallogr D Biol CrystallogrYear: 20096517618519171973
197.. Ban TA. The role of serendipity in drug discoveryDialogues Clin NeurosciYear: 20068244335
198.. Nurnberg HG,Hensley PL,Gelenberg AJ,Fava M,Lauriello J,Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trialJAMAYear: 2003289566412503977
199.. Kuipers W,Link R,Standaar PJ,Stoit AR,Wijngaarden I,Leurs R,Ijzerman AP. Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptorMol PharmacolYear: 1997518898969145928
200.. Kuipers W, Oliveira L, Paiva ACM, Rippman F, Sander C, IJzerman AP (1996) In: Findlay J (ed) Membrane protein models. Bios Scientific Publishers, Oxford
201.. GPCRDB information system for G protein-coupled receptors (2011) Accessed 6 Dec 2011
202.. Cherezov V,Rosenbaum DM,Hanson MA,Rasmussen SG,Thian FS,Kobilka TS,Choi HJ,Kuhn P,Weis WI,Kobilka BK,Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptorScienceYear: 20073181258126517962520
203.. Oliveira L,Paiva ACM,Vriend G. A common motif in G-protein-coupled seven transmembrane helix receptorsJ Comp aided Mol DesYear: 19937649658
204.. Oliveira L,Paiva ACM,Sander C,Vriend G. A common step for signal transduction in G protein-coupled receptorsTrends Pharmacol SciYear: 1994151701728091507
205.. Oliveira L,Paiva ACM,Vriend G. A low resolution model for the interaction of G proteins with G protein-coupled receptorsProtein EngYear: 1999121087109510611402
206.. Wacker D,Brown MA,Fenalti G,Katritch V,Abagyan R,Cherezov V,Stevens RC. Conserved binding mode of human beta(2) adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallographyJ Am Chem SocYear: 2010132114431144520669948
207.. Standfuss J,Xie G,Edwards PC,Burghammer M,Oprian DD,Schertler GFX. Crystal structure of a thermally stable rhodopsin mutantJ Mol BiolYear: 20073721179118817825322
208.. Serrano-Vega MJ,Magnani F,Shibata Y,Tate CG. Conformational thermostabilization of the b1-adrenergic receptor in a detergent-resistant form of the b1-adrenergic receptor in a detergent-resistant formProc Natl Acad Sci USAYear: 200810587788218192400
209.. Rasmussen SG,Choi HJ,Rosenbaum DM,Kobilka TS,Thian FS,Edwards PC,Burghammer M,Ratnala VR,Sanishvili R,Fischetti RF,Schertler GF,Weis WI,Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptorNatureYear: 200745038387717952055
210.. Rosenbaum DM,Zhang C,Lyons JA,Holl R,Aragao D,Arlow DH,Rasmussen SGF,Choi HJ,DeVree BT,Sunahara RK,Chae PS,Gellman SH,Dror RO,Shaw DE,Weis WI,Caffrey M,Gmeiner P,Kobilka BK. Structure and function of an irreversible agonist-beta(2) adrenoceptor complexNatureYear: 201146923624021228876
211.. Horn F,Bettler E,Oliveira L,Campagne F,Cohen FE,Vriend G. GPCRDB information system for G protein-coupled receptorsNucleic Acids ResYear: 20033129429712520006
212.. Horn F,Weare J,Beukers MW,Hörsch S,Bairoch A,Chen W,Edvardsen O,Campagne F,Vriend G. GPCRDB: an information system for G protein-coupled receptorsNucleic Acids ResYear: 1998262752799399852
213.. Vroling B,Thorne D,McDermott P,Attwood TK,Vriend G,Pettifer S. Integrating GPCR-specific information with full text articlesBMC BioinfoYear: 201112362
214.. Joosten HJ,Han Y,Niu W,Vervoort J,Dunaway-Mariano D,Schaap PJ. Identification of fungal oxaloacetate hydrolyase within the isocitrate lyase/PEP mutase enzyme superfamily using a sequence marker-based methodProteinsYear: 20087015716617654546
215.. Kuipers RK,Joosten HJ,Berkel WJ,Leferink NG,Rooijen E,Ittmann E,Zimmeren F,Jochens H,Bornscheuer U,Vriend G,dos Santos VA,Schaap PJ. 3DM: systematic analysis of heterogeneous superfamily data to discover protein functionalitiesProteinsYear: 20107820132101
216.. Kourist R,Jochens H,Bartsch S,Kuipers R,Padhi SK,Gall M,Böttcher D,Joosten HJ,Bornscheuer UT. The alpha/beta-hydrolase fold 3DM database (ABHDB) as a tool for protein engineeringChembiochemYear: 2010111635164320593436
217.. Kuipers R,Bergh T,Joosten HJ,Lekanne dit Deprez RH,Mannens MM,Schaap PJ. Novel tools for extraction and validation of disease-related mutations applied to Fabry diseaseHum MutatYear: 2010311026103220629180
218.. Cerdobbel A,Winter K,Aerts D,Kuipers R,Joosten HJ,Soetaert W,Desmet T. Increasing the thermostability of sucrose phosphorylase by a combination of sequence- and structure-based mutagenesisProtein Eng Des SelYear: 20112482983421900303
219.. Attwood TK,Kell DB,McDermott P,Marsh J,Pettifer SR,Thorne D. Calling international rescue: knowledge lost in literature and data landslide!Biochem JYear: 200942431733319929850
220.. Palczewski K,Kumasaka T,Hori T,Behnke CA,Motoshima H,Fox BA,Letrong I,Teller T,Okada T,Stenkamp RE,Yamamoto M,Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptorScienceYear: 200028973974510926528
221.. Oliveira L,Hulsen T,Lutje Hulsik D,Paiva AC,Vriend G. Heavier-than-air flying machines are impossibleFEBS LettYear: 200456426927315111108
222.. Wieland K,ter Laak AM,Smit MJ,Kühne R,Timmerman H,Leurs R. Mutational analysis of the antagonist-binding site of the histamine H(1) receptorJ Biol ChemYear: 1999274299943000010514483
223.. Nuclear Receptors 3DM (2011) Accessed 9 Dec 2011
224.. Stenson PD,Cooper DN. Prospects for the automated extraction of mutation data from the scientific literatureHum GenomicsYear: 201051421106485
225.. Venselaar H,Te Beek TA,Kuipers RK,Hekkelman ML,Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfacesBMC BioinfoYear: 201011548


[Figure ID: Fig1]
Fig. 1 

Amount of money spent in billion US$/NME (after Munos [7]). Munos summarises these numbers eloquently in his 2009 review, but you are also encouraged to read the commentary by Firestone [9]

[Figure ID: Fig2]
Fig. 2 

Methotrexate in the active site pocket of dihydrofolate reductase (PDBid:4DFR [14]). Next to a monochrome picture showing this same fit, Hol wrote: “As to whether a drug can actually reach its target, e.g. the active center of an enzyme, is primarily a spatial problem. Assuming that the structures of both components are known, computer graphics can help in checking the suitability of a potentially active substance. As example, the structure of the complex formed between a bacterial dihydrofolate-reductase, NADP and the anticancer drug methotrexate (gray dots) is shown on the right. As one can see, it fits” [13]

[Figure ID: Fig3]
Fig. 3 

Contour representation of key features from a CoMFA analysis of a series of coumarin substrates and inhibitors of cytochrome P4502A5 [Poso et al, adapted from the publicly available UCLA Chemistry 125 course]. The red and blue regions indicate positions where it would be favourable, respectively unfavourable to place a negative charge and the green/yellow regions where it would be favourable/unfavourable to locate bulky groups

[Figure ID: Fig4]
Fig. 4 

Ligand binding by Asn-386. Left: (part of) the X-ray structure of the β2 adrenoceptor bound to an inverse agonist that is ‘somewhat similar’ to (S)-penbutolol. Right: (S)-penbutolol binding of Asn-386 in serotonin 5HT-1A predicted long before the first GPCR structure data became available

[Figure ID: Fig5]
Fig. 5 

Left, one page from the Histamine H1 article by Wieland et al. [222] in which Trp161 is suggested to interact with the ligand while the PDF reader sidebar shows today’s interpretation that this tryptophan is facing outwards towards the lipid or a dimer partner. The original picture of the modelled active site is shown enlarged in the middle panel while the right hand side figure is a plot of the GPCRDB-derived model of this receptor. The GPCRDB does not (yet) dock ligands, so the ligand is represented by a hand-added gray ball

[Figure ID: Fig6]
Fig. 6 

Bargraph showing the number of ligand contacts per residue extracted from 776 nuclear receptor ligand binding domain structures plotted as function of their 3D numbers. The blue bars represent the number of contacts with agonistic compounds. The red bars indicate the number of contacts with antagonistic compounds. The residue with 3D number 26 is only bound to antagonistic compounds

[Figure ID: Fig7]
Fig. 7 

Cartoon representation of two superposed representative NR structures (one bound to an agonist; one bound to an antagonist). These two structures, obviously, differ most in the location of Helix 12. The blue ligands are agonists; the red ones are antagonists. The ligands were placed in the same orientation as found in their native PDB file. All PDB files were superposed on the representative NR structures. Residue 26, for which the antagonist interaction had been mentioned in the literature, is shown in yellow, as is residue for which Fig. 6 also indicates antagonist interactions, albeit with less antagonists than residue 26. This role of residue 29 might represent a novel finding. Figure made with the 3DM-plugin for the YASARA—WHAT IF suite

Article Categories:
  • Perspective

Keywords: Keywords Drug design, Protein modeling, QSAR, G-protein coupled receptors, Translational research, Review.

Previous Document:  Minimal polyketide pathway expression in an actinorhodin cluster-deleted and regulation-stimulated S...
Next Document:  Diffuse unilateral pediatric arteriopathy: successful treatment with repeated angioplasty.